PD-1/PD-L1抑制剂在小细胞肺癌中的研究与应用

国际肿瘤学杂志 Pub Date : 2019-11-08 DOI:10.3760/CMA.J.ISSN.1673-422X.2019.11.011

李桂香杜明丽赵磊吴文娟, Li Guixiang Du Mingli Zhao Lei Wu Wenjuan

{"title":"PD-1/PD-L1抑制剂在小细胞肺癌中的研究与应用","authors":"李桂香杜明丽赵磊吴文娟, Li Guixiang Du Mingli Zhao Lei Wu Wenjuan","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.11.011","DOIUrl":null,"url":null,"abstract":"Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a very high degree of malignancy. Currently, the standard treatment for SCLC is still chemoradiotherapy, and although SCLC is sensitive to chemotherapy in the early stage, recurrence and metastasis often occur due to drug resis-tance. In recent years, immunotherapy has made some progress in the study of SCLC. The immunodetection point programmed death-1 (PD-1) and its ligand (PD-L1) inhibitors, such as nivolumab, atezolizumab and pabolizumab, have shown good antitumor activity in clinical studies of SCLC, and PD-1/PD-L1 inhibitors combined with chemotherapy have shown better efficacy, providing a new strategy for the treatment of SCLC. \n \n \nKey words: \nSmall cell lung carcinoma; Immunotherapy; PD-1/PD-L1","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"239 1","pages":"695-698"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Research and application of PD-1/PD-L1 inhibitors in small cell lung cancer\",\"authors\":\"李桂香杜明丽赵磊吴文娟, Li Guixiang Du Mingli Zhao Lei Wu Wenjuan\",\"doi\":\"10.3760/CMA.J.ISSN.1673-422X.2019.11.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a very high degree of malignancy. Currently, the standard treatment for SCLC is still chemoradiotherapy, and although SCLC is sensitive to chemotherapy in the early stage, recurrence and metastasis often occur due to drug resis-tance. In recent years, immunotherapy has made some progress in the study of SCLC. The immunodetection point programmed death-1 (PD-1) and its ligand (PD-L1) inhibitors, such as nivolumab, atezolizumab and pabolizumab, have shown good antitumor activity in clinical studies of SCLC, and PD-1/PD-L1 inhibitors combined with chemotherapy have shown better efficacy, providing a new strategy for the treatment of SCLC. \\n \\n \\nKey words: \\nSmall cell lung carcinoma; Immunotherapy; PD-1/PD-L1\",\"PeriodicalId\":16120,\"journal\":{\"name\":\"国际肿瘤学杂志\",\"volume\":\"239 1\",\"pages\":\"695-698\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"国际肿瘤学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.11.011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际肿瘤学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.11.011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

小细胞肺癌(SCLC)是一种恶性程度很高的侵袭性神经内分泌癌。目前，SCLC的标准治疗仍是放化疗，尽管SCLC在早期对化疗敏感，但由于耐药，经常发生复发和转移。近年来，免疫治疗在SCLC的研究中取得了一些进展。免疫检查点程序性死亡-1 (PD-1)及其配体(PD-L1)抑制剂nivolumab、atezolizumab、pabolizumab等在SCLC的临床研究中显示出良好的抗肿瘤活性，PD-1/PD-L1抑制剂联合化疗显示出更好的疗效，为SCLC的治疗提供了新的策略。关键词:小细胞肺癌;免疫治疗;PD-1 / PD-L1

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Research and application of PD-1/PD-L1 inhibitors in small cell lung cancer

Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a very high degree of malignancy. Currently, the standard treatment for SCLC is still chemoradiotherapy, and although SCLC is sensitive to chemotherapy in the early stage, recurrence and metastasis often occur due to drug resis-tance. In recent years, immunotherapy has made some progress in the study of SCLC. The immunodetection point programmed death-1 (PD-1) and its ligand (PD-L1) inhibitors, such as nivolumab, atezolizumab and pabolizumab, have shown good antitumor activity in clinical studies of SCLC, and PD-1/PD-L1 inhibitors combined with chemotherapy have shown better efficacy, providing a new strategy for the treatment of SCLC. Key words: Small cell lung carcinoma; Immunotherapy; PD-1/PD-L1

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

国际肿瘤学杂志

自引率

0.00%

发文量

12123

期刊介绍：